All Episodes
GHAPPcast — 164 episodes · page 1 of 2
Linerixibat Medication Review
Podcast: Managing Fatigue and Pruritus in Your Patients With PBC
Podcast: How to Screen and Diagnose Cholestatic Liver Diseases
GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy
FAQ: Counseling Patients on Overt Hepatic Encephalopathy
FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy
Subgroup Analysis: Differences in Maintenance Dosing For UC and CD
Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC
Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease
FAQ: QUASAR Long Term Extension Interim Analysis
Medication Review: Guselkumab IV vs SC Formulation
FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease
FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease
Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy
Medication Review: Stable PK Supporting Continuous Inflammatory Control
Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab
Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD
Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?
Podcast: Best Practices For Patient Identification
Podcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference?
Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results
Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know
FAQ: Biomarkers: The Non-Invasive Future of HCC Detection
FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications
FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications?
FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH?
FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH?
Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment
APP Roundtable: Approach To Starting Treatments in Patients With CHB
APP Roundtable: Navigating Difficult Conversations in CHB
APP Roundtable: Addressing Co-Morbidities in CHB
FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History?
Journal Club: Review of Focused Recommendations for the Management of MASLD
Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations
FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients?
The Conversation That Matters: Talking to Patients About Obesity and IMIDs
From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs
GHAPPcast: Women of Childbearing Age With IBD
The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs
FAQ: How Do You Explain Remission To A Patient?
GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient
Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts
APP Insight: How Do You Develop a Treatment Plan for IBS-C? What Are Some Considerations?
GHAPPcast: IBS-C Therapies Explained: Helping Patients Understand Their Options
GHAPPcast: Smarter Surveillance: The Rise of Algorithms like GALAD and Their Path to Practice
FAQ: What Is the Importance of Biomarkers Such as Fecal Calprotectin and CRP?
FAQ: What Are the Next Steps When a Patient Still Has Active Disease When Taking Advanced Therapy?
APP Roundtable: Community Resources and Support Systems for CHB
APP Insight: Conducting Meaningful Conversations to Assess Therapy Impact
GHAPPcast: Decoding Diagnostics: Why Biomarker Development Phases Are Your Clinical Ally
GHAPPcast: Explaining IBS-C: Diagnosis and Communication That Builds Confidence
APP Insight: Evaluating Time to Response and Treatment Effectiveness
APP Insight: Why Is It Important to Let Patients Know There Are Different Options for Treatment?
Empowering PBC Patients: APPs’ Role in Education and Support
GHAPPcast: Payer Tutorial
APP Roundtable: Navigating Treatment Guidelines With CHB
APP Roundtable: Patient-Centric Care Approaches in PBC
APP Roundtable: Addressing Mental Health in Patients With PBC
GHAPPcast: Setting the Standard in Biomarker Validation: EDRN Example & Lessons from Liver Cancer
GHAPPcast: Navigating Difficult Conversations: Discussing prognosis and lifelong care in PBC
GHAPPcast: Collaborating Across Specialties: How APPs Can Work with Hepatologists & Other Providers in PBC Care
GHAPPcast: Managing PBC Symptoms in the Real World: Practical Tips for APPs
FAQ: What Is the Difference Between CIC and IBS-C?
GHAPPcast: Lifestyle and Nutrition Interventions for Constipation
APP Insight: Discussing Exercise as a Complement to IBS-C Treatment
GHAPPcast: Mental Health Issues and Symptoms Related to IBS-C
FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?
APP Roundtable: Future Directions in CHB Research
APP Roundtable: Navigating Treatment Guidelines in CHB
APP Insight: Provide Diagnostic Tips for IBS-C
APP Insight: Using the Bristol Stool Scale to Measure Response to Treatment
APP Roundtable: Challenges in Diagnosing CHB
APP Roundtable: Future Directions in PBC Research
APP Roundtable: Multidisciplinary Care Models in PBC Management
APP Roundtable: PBC Patient Perspectives & Advocacy
FAQ: What Are the Main Causes of IBS, and How Does the Disease Progress Over Time?
KOL Conversation: Setting Expectations When Initiating New Therapy
KOL Conversation: Diagnosing IBS With Confidence
KOL Conversation: Diagnosing EPI and Managing With The Appropriate PERT Dosing
KOL Conversation: Implementing the IBS Guidelines
GHAPPcast: The Clinical Utility of Guselkumab in CD
GHAPPcast: Not Responding to UDCA in the First Few Months, Need to Move on to Second-Line Therapy
GHAPPcast: Need for Earlier Evaluation of UDCA Response, Need for Earlier Consideration of Second-Line Therapy
GHAPPcast: Building a Sense of Urgency for PBC Patient Evaluation/Monitoring
GHAPPcast: Importance of Understanding Impact on Disease Outcomes: Progression to Fibrosis and Cirrhosis
GHAPPcast: Need for Clinicians to Better Understand The "Area Under the Curve" in Non-Response to UDCA
GHAPPcast: Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively
GHAPPcast: Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically
GHAPPcast: Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression
Journal Club: Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3
GHAPPcast: Simplifying Access: Evolving Drug Distribution Channels
GHAPPcast: Simplifying Access: Prior Authorization Part 2
GHAPPcast: Simplifying Access: Prior Authorization Part 1
Journal Club: Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study
GHAPPcast: The Clinical Utility of Guselkumab in UC
KOL: What Are the Most Critical Updates in Cirrhosis Research That Clinicians Should Be Aware Of?
KOL: How Can Healthcare Professionals Improve Patient Outcomes in Those with Cirrhosis?